The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment Read More »
Se sabe que el universo está en expansión, y esto podría llevarnos a creer que existe un centro (donde se produjo el Big Bang) desde el que se originó esta expansión. Sin embargo, no es así. El universo realmente no tiene un centro. Más bien, deber&ia …
¿La conducta del universo es la misma en todas sus regiones? Read More »
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the company’s forecasted dip in 2025 revenues.
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program Read More »
The approval comes days after Germany’s Merck KGaA confirmed it was in advanced talks to acquire SpringWorks.
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca Read More »
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP Read More »
The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including TIM-3, LAG-3, OX40 and GITR.
Incyte Backs Out of Immuno-Oncology Pact With Agenus Read More »
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer stepped in as CEO to answer a critical question: What’s next?
Vir Leans Into Immunology Roots After Flamed-Out COVID Fame Read More »
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron sues Sanofi over an alleged failure to provide adequate information about Dupixent sales.
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs Read More »
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
Trump’s Whiplash Policies Keep Pharmas on Their Toes Read More »
La noche esconde un universo lleno de vida y sorpresas. Mientras la mayoría de nosotros descansamos, cientos de especies se activan en la penumbra, desplegando adaptaciones asombrosas que les permiten sobrevivir y prosperar en ambientes oscuros. Adaptaciones para la vida en la oscuri …
